We transform the most promising oncology innovations into highly competitive opportunities that benefit patients, researchers, investors, and Ontario's economy. Cancer Breakthroughs. Realized.
FACIT Features: DNAstack to lead and develop COVID Cloud for Canada’s Digital Technology Supercluster
The COVID Cloud will enable accelerated and more insightful interpretation of COVID-19, leading to increased preparedness for future outbreaks, and identification of potential treatments.
FACIT is pleased to accept the invitation to join the national consortium as Lead Commercialization Advisor.
FACIT Features: Portfolio company KA Imaging secures FDA approval for portable dual-energy x-ray detector
Reveal™ enables bone and soft tissue differentiation in a single, highly sensitive x-ray exposure.
Since FACIT’s early seed investment in KA Imaging, the company has greatly expanded its IP portfolio, as well as the number of highly skilled jobs it has brought to Ontario.
Following other successful Canadian biotech IPOs this year, Fusion’s IPO represents the largest by an Ontario biotechnology company
FACIT congratulates Hamilton-based Fusion Pharma (NASDAQ: FUSN) on its initial public offering (IPO) with shares of the company beginning to trade on the Nasdaq Global Market exchange today.
Replica Analytics and Sunnybrook’s Czarnota Lab receive key seed funding to de-risk Ontario intellectual property
FACIT’s investments strategically address the seed-stage gap experienced by Ontario’s life sciences sector, fueling promising cancer breakthroughs towards a value inflection point and helping local start-ups establish and anchor jobs in the province.
FACIT recognized with 2020 Venture Capital Regional Impact Award by the Canadian Venture Capital & Private Equity Association (CVCA)
Award acknowledges FACIT’s commercialization impact in growing Ontario’s life sciences industry
FACIT’s award was specifically related to the 2019 historic US$1B partnership between its portfolio companies, Propellon Therapeutics and Triphase Accelerator, and US pharma giant Celgene (acquired by Bristol-Myers Squibb Company).
FACIT Features: OICR leads international team to generate world’s most comprehensive cancer genome map
FACIT congratulates its strategic partner, OICR, on its leading role in completing an unprecedented, multi-institutional study of whole cancer genomes, spanning 10 years.
The output from this global study vastly improves the fundamental understanding of cancer and will provide guidance and new directions for its diagnosis and treatment.